Patents by Inventor Ulrich Mengs

Ulrich Mengs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Silibinin component for the treatment of hepatitis
    Patent number: 9248115
    Abstract: The invention relates to the use of a silibinin component for the production of a medicament that is adapted for parenteral administration for the treatment of viral hepatitis, preferably of hepatitis B or C, in particular for the reduction of the virus load. The medicament preferably contains no silidianin and/or no silichristin and/or no isosilibinin.
    Type: Grant
    Filed: April 26, 2013
    Date of Patent: February 2, 2016
    Assignee: MADAUS GMBH
    Inventors: Lucio Claudio Rovati, Massimo Maria D'Amato, Ulrich Mengs, Ralf-Torsten Pohl, Peter Ferenci
  • Amorphous silibinin for the treatment of viral hepatitis
    Patent number: 8614341
    Abstract: The invention relates to a method for the preparation of amorphous silibinin (or its synonyms: silybin or silibin) derived from a milk thistle fruit extract having an increased release rate and improved absorbability or bioavailability, and to the use of amorphous silibinin for the treatment or prevention of liver diseases, preferably for the treatment of viral hepatitis, e.g. hepatitis B or C, in particular in a patient who will undergo or has undergone liver transplantation. Preferably, the amorphous silibinin is adapted for oral administration.
    Type: Grant
    Filed: May 14, 2010
    Date of Patent: December 24, 2013
    Assignee: Euromed S.A.
    Inventors: Lucio Claudio Rovati, Astrid Nagell, Aguirre Jaime Xiol, Prous Santiago Rull, Ralf-Torsten Pohl, Ulrich Mengs
  • SILIBININ COMPONENT FOR THE TREATMENT OF HEPATITIS
    Publication number: 20130236420
    Abstract: The invention relates to the use of a silibinin component for the production of a medicament that is adapted for parenteral administration for the treatment of viral hepatitis, preferably of hepatitis B or C, in particular for the reduction of the virus load. The medicament preferably contains no silidianin and/or no silichristin and/or no isosilibinin.
    Type: Application
    Filed: April 26, 2013
    Publication date: September 12, 2013
    Applicant: MADAUS GmbH
    Inventors: LUCIO CLAUDIO ROVATI, MASSIMO MARIA D'AMATO, ULRICH MENGS, RALF-TORSTEN POHL, PETER FERENCI
  • AMORPHOUS SILIBININ FOR THE TREATMENT OF VIRAL HEPATITIS
    Publication number: 20120108825
    Abstract: The invention relates to a method for the preparation of amorphous silibinin (or its synonyms: silybin or silibin) derived from a milk thistle fruit extract having an increased release rate and improved absorbability or bioavailability, and to the use of amorphous silibinin for the treatment or prevention of liver diseases, preferably for the treatment of viral hepatitis, e.g. hepatitis B or C, in particular in a patient who will undergo or has undergone liver transplantation. Preferably, the amorphous silibinin is adapted for oral administration.
    Type: Application
    Filed: May 14, 2010
    Publication date: May 3, 2012
    Applicant: Euromed S.A.
    Inventors: Lucio Claudio Rovati, Astrid Nagell, Aguirre Jaime Xiol, Prous Santiago Rull, Ralf-Torsten Pohl, Ulrich Mengs
  • Use of flavolignans as adjuvants in tumour therapy
    Patent number: 5714473
    Abstract: The present invention is concerned with the use of flavolignans as adjuvants in the case of chemotherapeutic tumour treatment and for the protection of cells in the urogenital region.
    Type: Grant
    Filed: January 24, 1995
    Date of Patent: February 3, 1998
    Assignee: Madaus AG
    Inventors: Hans Lentzen, Ulrich Mengs, Karl-Peter Odenthal, Hilmar Stolte